The biology of CML blast crisis.

Chronic myelogenous leukemia (CML) evolves from a chronic phase characterized by the Philadelphia chromosome as the sole genetic abnormality into blast crisis, which is often associated with additional chromosomal and molecular secondary changes. Although the pathogenic effects of most CML blast crisis secondary changes are still poorly understood, ample evidence suggests that the phenotype of CML blast crisis cells (enhanced proliferation and survival, differentiation arrest) depends on cooperation of BCR/ABL with genes dysregulated during disease progression. Most genetic abnormalities of CML blast crisis have a direct or indirect effect on p53 or Rb (or both) gene activity, which are primarily required for cell proliferation and survival, but not differentiation. Thus, the differentiation arrest of CML blast crisis cells is a secondary consequence of these abnormalities or is caused by dysregulation of differentiation-regulatory genes (ie, C/EBPalpha). Validation of the critical role of certain secondary changes (ie, loss of p53 or C/EBPalpha function) in murine models of CML blast crisis and in in vitro assays of BCR/ABL transformation of human hematopoietic progenitors might lead to the development of novel therapies based on targeting BCR/ABL and inhibiting or restoring the gene activity gained or lost during disease progression (ie, p53 or C/EBPalpha).

[1]  T. Skorski,et al.  BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. , 2006, Blood.

[2]  K. Bhalla,et al.  Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. , 2006, The New England journal of medicine.

[3]  J. Kutok,et al.  Absence of the transcription factor CCAAT enhancer binding protein alpha results in loss of myeloid identity in bcr/abl-induced malignancy. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Hongyue Dai,et al.  Gene expression changes associated with progression and response in chronic myeloid leukemia. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Guido Marcucci,et al.  The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. , 2005, Cancer cell.

[6]  J. Melo,et al.  Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. , 2005, Cancer research.

[7]  Martin A. Nowak,et al.  Dynamics of chronic myeloid leukaemia , 2005, Nature.

[8]  C. Sawyers,et al.  Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. , 2005, Blood.

[9]  A. Hardy,et al.  Mortality , 1953, The Panama Railroad.

[10]  I. Weissman,et al.  JunB Deficiency Leads to a Myeloproliferative Disorder Arising from Hematopoietic Stem Cells , 2004, Cell.

[11]  Laurie E Ailles,et al.  Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. , 2004, The New England journal of medicine.

[12]  M. Carroll,et al.  BCR/ABL translocates to the nucleus and disrupts an ATR-dependent intra-S phase checkpoint. , 2004, Cancer cell.

[13]  K. Miyazaki,et al.  Snail and SIP1 increase cancer invasion by upregulating MMP family in hepatocellular carcinoma cells , 2004, British Journal of Cancer.

[14]  A. Viale,et al.  The Oncogene Nup98-HOXA9 Induces Gene Transcription in Myeloid Cells* , 2004, Journal of Biological Chemistry.

[15]  K. Akashi,et al.  Inducible expression of BCR/ABL using human CD34 regulatory elements results in a megakaryocytic myeloproliferative syndrome. , 2003, Blood.

[16]  H. Kantarjian,et al.  Chromosomal abnormalities in Philadelphia chromosome‐negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome‐positive chronic myelogenous leukemia in chronic phase , 2003, Cancer.

[17]  Biao He,et al.  Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression , 2003, Oncogene.

[18]  Susan Branford,et al.  Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. , 2003, The New England journal of medicine.

[19]  A. Green,et al.  Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. , 2003, Blood.

[20]  A. Green,et al.  Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia. , 2003, Blood.

[21]  P. Laneuville,et al.  Measurement of genomic instability in preleukemic P190BCR/ABL transgenic mice using inter-simple sequence repeat polymerase chain reaction. , 2003, Cancer research.

[22]  A. Strife,et al.  Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies , 2003, Leukemia.

[23]  J. Radich,et al.  HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. , 2003, Blood.

[24]  Susan Branford,et al.  Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. , 2003, Blood.

[25]  Eric Deutsch,et al.  Down-regulation of BRCA1 in BCR-ABL-expressing hematopoietic cells. , 2003, Blood.

[26]  L. Starita,et al.  The multiple nuclear functions of BRCA1: transcription, ubiquitination and DNA repair. , 2003, Current opinion in cell biology.

[27]  H. Lodish,et al.  Cytokines and BCR-ABL mediate suppression of TRAIL-induced apoptosis through inhibition of forkhead FOXO3a transcription factor , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Irving L. Weissman,et al.  Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells , 2003, Nature.

[29]  T. Rabbitts,et al.  Engineering de novo reciprocal chromosomal translocations associated with Mll to replicate primary events of human cancer. , 2003, Cancer cell.

[30]  Francisco Cervantes,et al.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.

[31]  E. Montserrat,et al.  Genomic p16 abnormalities in the progression of chronic myeloid leukemia into blast crisis: a sequential study in 42 patients. , 2003, Experimental hematology.

[32]  Deanna Naeve,et al.  Arf induces p53-dependent and -independent antiproliferative genes. , 2003, Cancer research.

[33]  R. Braziel,et al.  Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate , 2003, Leukemia.

[34]  K. Krohn,et al.  Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. , 2003, Blood.

[35]  H. Endo,et al.  A Member of Forkhead Transcription Factor FKHRL1 Is a Downstream Effector of STI571-induced Cell Cycle Arrest in BCR-ABL-expressing Cells* , 2003, The Journal of Biological Chemistry.

[36]  M. Caligiuri,et al.  BCR/ABL activates mdm2 mRNA translation via the La antigen. , 2003, Cancer cell.

[37]  M. Jasin Homologous repair of DNA damage and tumorigenesis:the BRCA connection , 2002, Oncogene.

[38]  Hua Yu,et al.  Inhibition of Bcr–Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells , 2002, Oncogene.

[39]  G. Sauvageau,et al.  Oncogenic interaction between BCR-ABL and NUP98-HOXA9 demonstrated by the use of an in vitro purging culture system. , 2002, Blood.

[40]  Matthew B. Wilson,et al.  The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells , 2002, The EMBO journal.

[41]  Eduard Batlle,et al.  Snail Induction of Epithelial to Mesenchymal Transition in Tumor Cells Is Accompanied by MUC1 Repression andZEB1 Expression* , 2002, The Journal of Biological Chemistry.

[42]  Carlos L. Arteaga,et al.  PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization , 2002, Nature Medicine.

[43]  Alfonso Bellacosa,et al.  Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27Kip1 by PKB/Akt-mediated phosphorylation in breast cancer , 2002, Nature Medicine.

[44]  N. Raab-Traub,et al.  I-mfa Domain Proteins Interact with Axin and Affect Its Regulation of the Wnt and c-Jun N-Terminal Kinase Signaling Pathways , 2002, Molecular and Cellular Biology.

[45]  C. Verfaillie,et al.  Chronic myelogenous leukemia: mechanisms underlying disease progression , 2002, Leukemia.

[46]  J. Kuriyan,et al.  Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. , 2002, Cancer cell.

[47]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[48]  M. Wasik,et al.  Complementary functions of the antiapoptotic protein A1 and serine/threonine kinase pim-1 in the BCR/ABL-mediated leukemogenesis. , 2002, Blood.

[49]  L. Campbell,et al.  Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instability. , 2002, Blood.

[50]  D. Gilliland,et al.  Focus on acute leukemias. , 2002, Cancer cell.

[51]  H. Iwasaki,et al.  Critical role for Gab2 in transformation by BCR/ABL. , 2002, Cancer cell.

[52]  R. Fishel,et al.  Fusion Tyrosine Kinases Induce Drug Resistance by Stimulation of Homology-Dependent Recombination Repair, Prolongation of G2/M Phase, and Protection from Apoptosis , 2002, Molecular and Cellular Biology.

[53]  D. Housman,et al.  A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9 , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[54]  W. Hahn,et al.  Modelling the molecular circuitry of cancer , 2002, Nature Reviews Cancer.

[55]  T. Skorski,et al.  Oncogenic tyrosine kinases and the dna-damage response , 2002, Nature Reviews Cancer.

[56]  R. Herrmann,et al.  High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. , 2002, Blood.

[57]  AC Eaves,et al.  Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia , 2002, Leukemia.

[58]  G. Hoser,et al.  DOES THE BCR/ABL‐MEDIATED INCREASE IN THE EFFICACY OF DNA REPAIR PLAY A ROLE IN THE DRUG RESISTANCE OF CANCER CELLS? , 2002, Cell biology international.

[59]  Yunmei Ma,et al.  Hairpin Opening and Overhang Processing by an Artemis/DNA-Dependent Protein Kinase Complex in Nonhomologous End Joining and V(D)J Recombination , 2002, Cell.

[60]  C. Kollman,et al.  Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. , 2002, Blood.

[61]  J. Melo,et al.  Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia: possible inadequacy of a negative feedback mechanism. , 2002, Blood.

[62]  B. Johansson,et al.  Cytogenetic and Molecular Genetic Evolution of Chronic Myeloid Leukemia , 2002, Acta Haematologica.

[63]  J. Downing,et al.  Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. , 2002, Cancer cell.

[64]  G. Daley,et al.  Critical role for cyclin D2 in BCR/ABL-induced proliferation of hematopoietic cells. , 2002, Cancer research.

[65]  R. Ren,et al.  Cooperation of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia , 2001, Oncogene.

[66]  L. Chin,et al.  Impaired nonhomologous end-joining provokes soft tissue sarcomas harboring chromosomal translocations, amplifications, and deletions. , 2001, Molecular cell.

[67]  Yong Liao,et al.  HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation , 2001, Nature Cell Biology.

[68]  E. Lam,et al.  Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts. , 2001, Cancer research.

[69]  R. Fishel,et al.  BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. , 2001, Molecular cell.

[70]  A. Berns,et al.  Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice , 2001, Nature.

[71]  D. Carrasco,et al.  Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis , 2001, Nature.

[72]  L. Mayo,et al.  A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[73]  P. Pandolfi,et al.  Mzf1 controls cell proliferation and tumorigenesis. , 2001, Genes & development.

[74]  E. Lam,et al.  BCR-ABL and Interleukin 3 Promote Haematopoietic Cell Proliferation and Survival through Modulation of Cyclin D2 and p27Kip1 Expression* , 2001, The Journal of Biological Chemistry.

[75]  J. Squire,et al.  Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis. , 2001, Blood.

[76]  George Iliakis,et al.  Efficient rejoining of radiation-induced DNA double-strand breaks in vertebrate cells deficient in genes of the RAD52 epistasis group , 2001, Oncogene.

[77]  C. Sawyers,et al.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.

[78]  J. Bourhis,et al.  BCR-ABL down-regulates the DNA repair protein DNA-PKcs. , 2001, Blood.

[79]  R. Schiestl,et al.  Homologous recombination as a mechanism of carcinogenesis. , 2001, Biochimica et biophysica acta.

[80]  W. R. Bishop,et al.  Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. , 2001, Blood.

[81]  U. Thorsteinsdóttir,et al.  NUP98–HOXA9 expression in hemopoietic stem cells induces chronic and acute myeloid leukemias in mice , 2001, The EMBO journal.

[82]  M. Caligiuri,et al.  Expression profiling reveals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[83]  M. Loda,et al.  BCR/ABL Regulates Expression of the Cyclin-dependent Kinase Inhibitor p27Kip1 through the Phosphatidylinositol 3-Kinase/AKT Pathway* , 2000, The Journal of Biological Chemistry.

[84]  T. Ley,et al.  Acquired, nonrandom chromosomal abnormalities associated with the development of acute promyelocytic leukemia in transgenic mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[85]  Jean Y. J. Wang Regulation of cell death by the Abl tyrosine kinase , 2000, Oncogene.

[86]  D. Scadden,et al.  Stem cell repopulation efficiency but not pool size is governed by p27kip1 , 2000, Nature Medicine.

[87]  M. Roussel,et al.  Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of stat5. , 2000, Blood.

[88]  M. Hallek,et al.  Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines. , 2000, Blood.

[89]  R. Salgia,et al.  The BCR/ABL Tyrosine Kinase Induces Production of Reactive Oxygen Species in Hematopoietic Cells* , 2000, The Journal of Biological Chemistry.

[90]  A. Elmaagacli,et al.  The amount of BCR-ABL fusion transcripts detected by the real-time quantitative polymerase chain reaction method in patients with Philadelphia chromosome positive chronic myeloid leukemia correlates with the disease stage , 2000, Annals of Hematology.

[91]  P. Laneuville,et al.  Increase in mutant frequencies in mice expressing the BCR-ABL activated tyrosine kinase , 2000, Leukemia.

[92]  P. Guldberg,et al.  Mutational analysis of the tumour suppressor gene MMAC1/PTEN in malignant myeloid disorders , 2000, European journal of haematology.

[93]  Shawn M. Sweeney,et al.  Versatility of BCR/ABL-expressing leukemic cells in circumventing proapoptotic BAD effects. , 2000, Blood.

[94]  D. Ramsden,et al.  Ku Recruits the XRCC4-Ligase IV Complex to DNA Ends , 2000, Molecular and Cellular Biology.

[95]  E. Andreu,et al.  Blockade of the Bcr-Abl Kinase Activity Induces Apoptosis of Chronic Myelogenous Leukemia Cells by Suppressing Signal Transducer and Activator of Transcription 5–Dependent Expression of Bcl-XL , 2000, The Journal of experimental medicine.

[96]  D. Scadden,et al.  Hematopoietic stem cell quiescence maintained by p21cip1/waf1. , 2000, Science.

[97]  Y. Yazaki,et al.  Acquired loss of p53 induces blastic transformation in p210(bcr/abl)-expressing hematopoietic cells: a transgenic study for blast crisis of human CML. , 2000, Blood.

[98]  N. Tuteja,et al.  Ku Autoantigen: A Multifunctional DNA-Binding Protein , 2000, Critical reviews in biochemistry and molecular biology.

[99]  Á. Borbély,et al.  Alterations of P53 and RB Genes and the Evolution of the Accelerated Phase of Chronic Myeloid Leukemia , 2000, Leukemia & lymphoma.

[100]  T. Ley,et al.  A bcr-3 isoform of RARα-PML potentiates the development of PML-RARα-driven acute promyelocytic leukemia , 1999 .

[101]  C. Eaves,et al.  Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[102]  S. Krichevsky,et al.  ABL1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia. , 1999, Blood.

[103]  L. Pfeffer,et al.  NF-κB activation by tumour necrosis factor requires the Akt serine–threonine kinase , 1999, Nature.

[104]  Å. Borg,et al.  Isochromosome 17q in blast crisis of chronic myeloid leukemia and in other hematologic malignancies is the result of clustered breakpoints in 17p11 and is not associated with coding TP53 mutations. , 1999, Blood.

[105]  A. Leutz,et al.  Separation of C/EBPalpha-mediated proliferation arrest and differentiation pathways. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[106]  A. Levine,et al.  P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[107]  D. H. Randle,et al.  Tumor spectrum in ARF-deficient mice. , 1999, Cancer research.

[108]  B. Calabretta,et al.  Signal Transducer and Activator of  Transcription (STAT)5 Activation by BCR/ABL Is Dependent on Intact Src Homology (SH)3 and SH2 Domains of BCR/ABL and Is Required for Leukemogenesis , 1999, The Journal of Experimental Medicine.

[109]  M. Greenberg,et al.  Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor , 1999, Cell.

[110]  Y. Yazaki,et al.  The t(3;21) Fusion Product, AML1/Evi-1, Interacts With Smad3 and Blocks Transforming Growth Factor-β–Mediated Growth Inhibition of Myeloid Cells , 1998 .

[111]  Jon C. Aster,et al.  Efficient and Rapid Induction of a Chronic Myelogenous Leukemia-Like Myeloproliferative Disease in Mice Receiving P210 bcr/abl-Transduced Bone Marrow , 1998 .

[112]  J. Melo,et al.  The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. , 1998, Blood.

[113]  R. DePinho,et al.  p19(Arf) induces p53-dependent apoptosis during abelson virus-mediated pre-B cell transformation. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[114]  K. Mills,et al.  c-myc locus amplification and the acquisition of trisomy 8 in the evolution of chronic myeloid leukaemia. , 1998, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.

[115]  R. D. Williams,et al.  Chronic isofenphos poisoning: case report of agnogenic myeloid metaplasia with a rapid progression into acute myeloid leukemia. , 1998, Leukemia research.

[116]  J. Cleveland,et al.  Selective regulation of Bcl-XL by a Jak kinase-dependent pathway is bypassed in murine hematopoietic malignancies. , 1998, Genes & development.

[117]  K. Irie,et al.  The oncoprotein Evi-1 represses TGF-β signalling by inhibiting Smad3 , 1998, Nature.

[118]  B. Calabretta,et al.  Role of p53 in hematopoietic recovery after cytotoxic treatment. , 1998, Blood.

[119]  D. Cortez,et al.  A requirement for NF-κB activation in Bcr–Abl-mediated transformation , 1998 .

[120]  Y. Yazaki,et al.  Development of acute lymphoblastic leukemia and myeloproliferative disorder in transgenic mice expressing p210bcr/abl: a novel transgenic model for human Ph1-positive leukemias. , 1998, Blood.

[121]  G. Krystal,et al.  BCR – ABL accelerates C2-ceramide-induced apoptosis , 1998, Oncogene.

[122]  Richard A. Ashmun,et al.  Tumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19 ARF , 1997, Cell.

[123]  P. Rothman,et al.  Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. , 1997, Journal of immunology.

[124]  S. R. Datta,et al.  Akt Phosphorylation of BAD Couples Survival Signals to the Cell-Intrinsic Death Machinery , 1997, Cell.

[125]  B. Calabretta,et al.  Transformation of hematopoietic cells by BCR/ABL requires activation of a PI‐3k/Akt‐dependent pathway , 1997, The EMBO journal.

[126]  A. Órfão,et al.  A BCR-ABL(p190) fusion gene made by homologous recombination causes B-cell acute lymphoblastic leukemias in chimeric mice with independence of the endogenous bcr product. , 1997, Blood.

[127]  M. Lieber,et al.  Activity of DNA ligase IV stimulated by complex formation with XRCC4 protein in mammalian cells , 1997, Nature.

[128]  L. Varticovski,et al.  Tyrosine phosphorylation of p120cbl in BCR/abl transformed hematopoietic cells mediates enhanced association with phosphatidylinositol 3-kinase , 1997, Oncogene.

[129]  K. Kinzler,et al.  Constitutive Transcriptional Activation by a β-Catenin-Tcf Complex in APC−/− Colon Carcinoma , 1997, Science.

[130]  A. Levine p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[131]  D. Tenen,et al.  Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[132]  J. Goldman,et al.  Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16‐year period , 1997, British journal of haematology.

[133]  R. V. van Etten,et al.  P210 and P190BCR/ABL Induce the Tyrosine Phosphorylation and DNA Binding Activity of Multiple Specific STAT Family Members* , 1996, The Journal of Biological Chemistry.

[134]  B. Calabretta,et al.  Blastic transformation of p53-deficient bone marrow cells by p210bcr/abl tyrosine kinase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[135]  L. Varticovski,et al.  BCR/abl leads to the constitutive activation of Stat proteins, and shares an epitope with tyrosine phosphorylated Stats. , 1996, Leukemia.

[136]  J. Melo,et al.  The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. , 1996, Blood.

[137]  B. Druker,et al.  PI 3-kinase activation in BCR/abl-transformed hematopoietic cells does not require interaction of p85 SH2 domains with p210 BCR/abl , 1996 .

[138]  T. Jacks,et al.  Mutations in the p53 and SCID genes cooperate in tumorigenesis. , 1996, Genes & development.

[139]  G. Zon,et al.  Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blast crisis in SCID mice. , 1996, Blood.

[140]  C. Sawyers,et al.  Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. , 1996, Oncogene.

[141]  T. Rabbitts,et al.  An Mll–AF9 Fusion Gene Made by Homologous Recombination Causes Acute Leukemia in Chimeric Mice: A Method to Create Fusion Oncogenes , 1996, Cell.

[142]  M. Horowitz,et al.  Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. , 1996, Bone marrow transplantation.

[143]  L. Chin,et al.  Role of the INK4a Locus in Tumor Suppression and Cell Mortality , 1996, Cell.

[144]  J. Griffin,et al.  Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl , 1996, The Journal of experimental medicine.

[145]  J. Dick,et al.  Normal and leukemic SCID-repopulating cells (SRC) coexist in the bone marrow and peripheral blood from CML patients in chronic phase, whereas leukemic SRC are detected in blast crisis. , 1996, Blood.

[146]  A. Feinberg,et al.  Fusion of the nucleoporin gene NUP98 to HOXA9 by the chromosome translocation t(7;11)(p15;p15) in human myeloid leukaemia , 1996, Nature Genetics.

[147]  V. Kaartinen,et al.  BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice. , 1995, Blood.

[148]  N. Heisterkamp,et al.  CRKL Links p210BCR/ABL with Paxillin in Chronic Myelogenous Leukemia Cells (*) , 1995, The Journal of Biological Chemistry.

[149]  F. Ragione,et al.  Involvement of the cyclin‐dependent kinase‐4 inhibitor (CDKN2) gene in the pathogenesis of lymphoid blast crisis of chronic myelogenous leukaemia , 1995, British journal of haematology.

[150]  B Calabretta,et al.  Overexpression of the zinc finger protein MZF1 inhibits hematopoietic development from embryonic stem cells: correlation with negative regulation of CD34 and c-myb promoter activity , 1995, Molecular and cellular biology.

[151]  G. Huez,et al.  Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. , 1995, Blood.

[152]  D. Cortez,et al.  Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis , 1995, Molecular and cellular biology.

[153]  A. Shinohara,et al.  Homologous recombination and the roles of double-strand breaks. , 1995, Trends in biochemical sciences.

[154]  O. Witte,et al.  Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene , 1995, Cell.

[155]  T. Lion,et al.  Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression. , 1995, Blood.

[156]  G. Zon,et al.  Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. , 1995, Blood.

[157]  Y. Yazaki,et al.  Expression of p210bcr/abl by metallothionein promoter induced T-cell leukemia in transgenic mice. , 1995, Blood.

[158]  Y. Yazaki,et al.  Dual functions of the AML1/Evi-1 chimeric protein in the mechanism of leukemogenesis in t(3;21) leukemias , 1995, Molecular and cellular biology.

[159]  J. Goldman,et al.  Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. , 1995, Blood.

[160]  C. Sawyers,et al.  Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene , 1995, The Journal of experimental medicine.

[161]  K. Mills,et al.  No evidence for microsatellite instability or consistent loss of heterozygosity at selected loci in chronic myeloid leukaemia blast crisis. , 1994, Leukemia.

[162]  T. Mimori,et al.  DNA-dependent protein kinase (Ku protein-p350 complex) assembles on double-stranded DNA. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[163]  F. Watzinger,et al.  Absence of N-ras mutations in myeloid and lymphoid blast crisis of chronic myeloid leukemia. , 1994, Cancer research.

[164]  G. Zon,et al.  Negative regulation of p120GAP GTPase promoting activity by p210bcr/abl: implication for RAS-dependent Philadelphia chromosome positive cell growth , 1994, The Journal of experimental medicine.

[165]  B. Zehnbauer,et al.  Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. , 1994, Blood.

[166]  Y. Yazaki,et al.  Generation of the AML1‐EVI‐1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia. , 1994, The EMBO journal.

[167]  S. Seeber,et al.  Analysis of the p53 gene in patients with isochromosome 17q and Ph1-positive or -negative myeloid leukemia. , 1993, Leukemia research.

[168]  S. Jackson,et al.  The DNA-dependent protein kinase: Requirement for DNA ends and association with Ku antigen , 1993, Cell.

[169]  M. Vekemans,et al.  Clonal evolution in a myeloid cell line transformed to interleukin-3 independent growth by retroviral transduction and expression of p210bcr/abl. , 1992, Blood.

[170]  C. Sawyers,et al.  Dominant negative MYC blocks transformation by ABL oncogenes , 1992, Cell.

[171]  M. Greaves,et al.  Restricted oncogenicity of BCR/ABL p190 in transgenic mice. , 1992, Cancer research.

[172]  L. Donehower,et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.

[173]  D. Kioussis,et al.  Humanbcr-abl gene has a lethal effect on embryogenesis , 1991, Transgenic Research.

[174]  H. Saito,et al.  Absence of the human retinoblastoma gene product in the megakaryoblastic crisis of chronic myelogenous leukemia. , 1991, Blood.

[175]  L. Deaven,et al.  A retinoic acid-responsive human zinc finger gene, MZF-1, preferentially expressed in myeloid cells. , 1991, The Journal of biological chemistry.

[176]  A. Berrebi,et al.  p53 in chronic myelogenous leukemia in acute phase. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[177]  J. Wang,et al.  Activation of tyrosinase kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins , 1991, Molecular and cellular biology.

[178]  G. Daley,et al.  Activation of phosphatidylinositol 3-kinase in cells expressing abl oncogene variants , 1991, Molecular and cellular biology.

[179]  J. Mushinski,et al.  Alternative splicing of RNAs transcribed from the human c-myb gene , 1990, Molecular and cellular biology.

[180]  A. Elefanty,et al.  bcr‐abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. , 1990, The EMBO journal.

[181]  G. Jenster,et al.  Acute leukaemia in bcr/abl transgenic mice , 1990, Nature.

[182]  O. Witte,et al.  Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. , 1990, Science.

[183]  G. Daley,et al.  Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. , 1990, Science.

[184]  S. Benchimol,et al.  Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[185]  H. Kantarjian,et al.  Ras oncogene mutations are rare late stage events in chronic myelogenous leukemia. , 1989, Blood.

[186]  S. Collins,et al.  Rare occurrence of N-ras point mutations in Philadelphia chromosome positive chronic myeloid leukemia. , 1989, Blood.

[187]  G. Daley,et al.  Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[188]  H. Kantarjian,et al.  Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. , 1987, The American journal of medicine.

[189]  O. Witte,et al.  In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[190]  R. Kurzrock,et al.  Molecular characteristics of chronic myelogenous leukemia in blast crisis. , 1987, Cancer genetics and cytogenetics.

[191]  Bruce A. Roe,et al.  Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene , 1986, Cell.

[192]  G. Daley,et al.  The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. , 1986, Science.

[193]  L. Gaboury,et al.  Unregulated proliferation of primitive chronic myeloid leukemia progenitors in the presence of normal marrow adherent cells. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[194]  O. Witte,et al.  Detection of c-abl tyrosine kinase activity in vitro permits direct comparison of normal and altered abl gene products , 1985, Molecular and cellular biology.

[195]  M. Groudine,et al.  Amplification of endogenous myc-related DNA sequences in a human myeloid leukaemia cell line , 1982, Nature.

[196]  E. Niebuhr Cytologic observations in 35 individuals with a 5p- karyotype , 1978, Human Genetics.

[197]  E. Fleischman,et al.  Chromosome abnormalities and clinical and morphologic manifestations of chronic myeloid leukemia , 1978, Human Genetics.

[198]  Spiers As The clinical features of chronic granulocytic leukaemia. , 1977 .

[199]  J. Rowley A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining , 1973, Nature.

[200]  S. Iacobelli,et al.  Design and Methods , 2022 .

[201]  J. Melo,et al.  Molecular profiling of CD34+ cells identifies low expression of CD7 with high expression of proteinase 3 or elastase as predictors of longer survival in CML patients (*) , 2005 .

[202]  O. Fromigué,et al.  Sp1/Sp3 and the myeloid zinc finger gene MZF1 regulate the human N-cadherin promoter in osteoblasts. , 2005, Experimental cell research.

[203]  J. Mcwhirter,et al.  Activation of Tyrosine Kinase and Microfilament-Binding Functions of c-abl by bcr Sequences in bcrlabl Fusion Proteins , 2004 .

[204]  R. Nusse,et al.  Convergence of Wnt, beta-catenin, and cadherin pathways. , 2004, Science.

[205]  H. Kantarjian,et al.  Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. , 2003, Blood.

[206]  M. Caligiuri,et al.  BCR-ABL suppresses C/EBPα expression through inhibitory action of hnRNP E2 , 2002, Nature Genetics.

[207]  J. Slingerland,et al.  PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest , 2002, Nature Medicine.

[208]  M. Caligiuri,et al.  BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2. , 2002, Nature genetics.

[209]  T. Maniatis,et al.  NF-(cid:1) B signaling pathways in mammalian and insect innate immunity , 2001 .

[210]  D. Tenen,et al.  Reversibility of acute B-cell leukaemia induced by BCR–ABL1 , 2000, Nature Genetics.

[211]  C. Verfaillie,et al.  Abnormal integrin-mediated regulation of chronic myelogenous leukemia CD34 1 cell proliferation: BCR y ABL up-regulates the cyclin-dependent kinase inhibitor, p27 Kip , which is relocated to the cell cytoplasm and incapable of regulating cdk2 activity , 2000 .

[212]  T. Ley,et al.  A bcr-3 isoform of RARalpha-PML potentiates the development of PML-RARalpha-driven acute promyelocytic leukemia. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[213]  S. Krichevsky,et al.  ABL 1 Methylation Is a Distinct Molecular Event Associated With Clonal Evolution of Chronic Myeloid Leukemia , 1999 .

[214]  M. Tommasino,et al.  Separation of C y EBP a -mediated proliferation arrest and differentiation pathways , 1999 .

[215]  Y. Yazaki,et al.  The t(3;21) fusion product, AML1/Evi-1, interacts with Smad3 and blocks transforming growth factor-beta-mediated growth inhibition of myeloid cells. , 1998, Blood.

[216]  D. Cortez,et al.  A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. , 1998, Genes & development.

[217]  H. Koeffler,et al.  Absence of microsatellite instability during the progression of chronic myelocytic leukemia , 1997, Leukemia.

[218]  M. Bar‐eli,et al.  Abnormalities of the retinoblastoma gene in the pathogenesis of acute leukemia. , 1991, Blood.

[219]  A. Strife,et al.  Biology of chronic myelogenous leukemia: is discordant maturation the primary defect? , 1988, Seminars in hematology.

[220]  M. Groudine,et al.  Chronic myelogenous leukemia: amplification of a rearranged c-abl oncogene in both chronic phase and blast crisis. , 1987, Blood.

[221]  M. Andreeff Cell kinetics of leukemia. , 1986, Seminars in hematology.

[222]  H. Messner,et al.  Pluripotent hemopoietic progenitors (CFU-GEMM) in chronic myelogenous leukemia. , 1983, International journal of cell cloning.

[223]  P. Nowell,et al.  A minute chromosome in human chronic granulocytic leukemia , 1960 .